Regenique Group ^{Filed Terms, Nasdaq: RGGG}

We offer a broad range of non-surgical, minimally invasive treatments to our customers in our clinics. The technological concept, procedures and equipment used to administer such treatments are carefully selected by our experienced doctors. Our treatments are designed based on scientific evidence and delivered by personnel with medical knowledge, training and experience. Our services can be classified into two categories: bio-regenerative treatments and medi-aesthetics treatments. Bio-regenerative treatments are generally marketed as aesthetics solutions at the forefront of our industry. They are grounded on the skin’s natural ability to regenerate and repair itself through the use of natural bio-cosmeceutical products, such as plant-based exosomes and stem cells, as skin boosters. Medi-aesthetics treatments are solutions delivered through the use of technologies that are regarded as the industry norm, including non-invasive procedures of laser and other energy treatments and minimally invasive procedures using botox and other chemical ingredients. 2023 marked a pivotal milestone for us. In early 2023, we started building a strategic partnership with Supergenics Berhad, a life science and biotechnology company listed on the Malaysia stock exchange. Their commitment to innovation is exemplified by their science-backed, proprietary methods and patents in stem cell technology, which includes high-yield culture of WJ-MSCs.